Specify Company / Ticker to Get the Summary
Dividend History BIVI
Dividend Analytics BIVI
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Biovie Inc
BIVIBioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. Address: 680 West Nye Lane, Carson City, NV, United States, 89703
Analytics
WallStreet Target Price
6.00 USDP/E Ratio
–Dividend Yield
–Financials BIVI
Results | 2019 | Dynamics |